Company Update (NYSE:MRK): Merck’s once-weekly diabetes drug approved in Japan

[Reuters] – Merck & CO said its Type 2 diabetes drug had been approved in Japan, marking the first approval for the once-weekly drug. The drug, omarigliptin, belongs to the same class of . . . → Read More: Company Update (NYSE:MRK): Merck’s once-weekly diabetes drug approved in Japan Similar Articles: Market Update (NYSE:MRK): Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal Company Update: Merck & Co Inc (NYSE:MRK) – Award-Winning Actress S. Epatha Merkerson, Merck and the American Diabetes Association Challenge African Americans with Type 2 Diabetes to Get to Their A1C Goal Market Update (NYSE:MRK): Tim McGraw, Merck and the American Diabetes Association Challenge Americans with Type 2 Diabetes to Get to Their A1C Goal